دورية أكاديمية
Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis.
| العنوان: | Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Liu B; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada., Grindrod N; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada., Meyers BM; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada., Freiburger S; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada., Boldt G; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada., Malik A; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada., Jairam MP; Brigham and Women's Hospital, Harvard Medical School, Harvard University, Boston, MA, USA., Brahmania M; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada., Cardarelli Leite L; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada., Simone CB 2nd; New York Proton Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chow R; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; New York Proton Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lock M; London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada. |
| المصدر: | Annals of palliative medicine [Ann Palliat Med] 2023 Nov; Vol. 12 (6), pp. 1165-1174. Date of Electronic Publication: 2023 Oct 27. |
| نوع المنشور: | Meta-Analysis; Systematic Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: AME Publishing Company Country of Publication: China NLM ID: 101585484 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2224-5839 (Electronic) Linking ISSN: 22245820 NLM ISO Abbreviation: Ann Palliat Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hong Kong : AME Publishing Company |
| مواضيع طبية MeSH: | Carcinoma, Hepatocellular*/complications , Carcinoma, Hepatocellular*/therapy , Liver Neoplasms*/therapy , Liver Neoplasms*/drug therapy , Chemoembolization, Therapeutic*/adverse effects , Venous Thrombosis*/therapy, Humans ; Sorafenib/therapeutic use ; Portal Vein ; Treatment Outcome |
| مستخلص: | Background: A number of therapeutic treatment strategies exist for patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT). The aim of this review is to provide a current understanding of treatment options and determine the relative effectiveness of treatment options in preventing mortality over 24 months. Methods: A search was conducted in PubMed, EMBASE and Cochrane CENTRAL from 2007 to 2022. Articles were screened to identify those that reported on all-cause mortality among treated, non-palliative patients with HCC and PVT. Study quality was assessed using the Cochrane Risk of Bias in Non-Randomized Studies of Interventions tool (ROBINS-1). Mortality rates at prespecified timepoints between 6 and 24 months were extracted and summarized using a random-effects DerSimonian-Laird model. This review was registered a priori on PROSPERO (CRD42022290708). Results: When comparing radiotherapy (RT) to sorafenib and combined transarterial chemoembolization (TACE), there was a trend that RT yields better survival at 6 months [odds ratio (OR) 0.70, 95% confidence interval (CI): 0.28-1.76]. When comparing sorafenib to Y90 and RT, sorafenib was associated with higher odds for mortality at 6 months (OR 2.20, 95% CI: 1.11-4.39). No significant differences were noticed from 12 to 24 months. Conclusions: Future strategies for HCC with PVT should look at the combination of radiation and systemic treatments either concurrently or sequentially. |
| فهرسة مساهمة: | Keywords: Radiotherapy (RT); hepatocellular carcinoma patients (HCC patients); portal vein thrombosis (PVT); sorafenib; transarterial chemoembolization (TACE) |
| المشرفين على المادة: | 9ZOQ3TZI87 (Sorafenib) |
| تواريخ الأحداث: | Date Created: 20231112 Date Completed: 20231216 Latest Revision: 20231216 |
| رمز التحديث: | 20231217 |
| DOI: | 10.21037/apm-23-463 |
| PMID: | 37953217 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2224-5839 |
|---|---|
| DOI: | 10.21037/apm-23-463 |